Ranbaxy Files For Phase I Trial On First Compound From GSK Deal
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials